Las Vegas, NV -- (SBWIRE) -- 10/15/2013 -- Beststocksondemand.com, is a financial newsletter and blog focused on shedding light on under-discovered small cap companies. Our team of professionals from various backgrounds work diligently to bring our members the best penny stock picks, stock market commentary, and news on all types of OTCBB and Pink Sheet companies, Acorda Therapeutics Inc (NASDAQ:ACOR), GSV Capital Corp (NASDAQ:GSVC), Inovio Pharmaceuticals Inc (NYSEMKT:INO), Prosensa Holding NV (NASDAQ:RNA)
Acorda Therapeutics Inc (NASDAQ:ACOR) was a volume gainer of 1.00 million shares and the average volume of the stock remained 248,093shares. The stock opened the session at $35.32 and finished at the end of the day at $32.50 and the stock plunged -8.04%.The market capitalization of the stock remained 1.32 billion. The half-yearly trend of the stock remained positive 3.11 %. Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP).
Will ACOR Bounce Back After yesterday’s Sharp Sell off? Find Out Here
In the preceding trading session, GSV Capital Corp (NASDAQ:GSVC) exchanged 323,460 shares and the average volume remained 975,499 shares. The stock closed the session at $15.30 with the gain of 0.07%. Tracking three months and 6 months trends, the stock was at of 89.83% and 92.7%, respectively. GSV Capital Corp. (GSV Capital), formerly NeXt Innovation Corp., is a development-stage company. The Company is an externally managed, non-diversified closed-end management investment company. The Company’s investment objective is to maximize capital appreciation. The Company will seek to achieve its investment objective by investing primarily in privately held high growth venture backed companies and select mid cap and large cap publicly traded companies.
Is it the Right to Grab GSV after the Recent Slump? Get Free Trend Analysis Here
Inovio Pharmaceuticals Inc (NYSEMKT:INO) decreased -7.77% and its closing price was $1.90. The volume of the stock was 6.44 million shares and the average volume remained 8.77 million shares. Yesterday, the stock traded amid the day price range of $1.86 - $2.02. The market capitalization of the stock remained 360.82 million. The beta of the stock remained 3.32.I novio Pharmaceuticals, Inc. is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine.
Will INO Reach the Bottom after Yesterday’s Correction? Find Out Here
Prosensa Holding NV (NASDAQ:RNA) exchanged 432,601 shares in the previous trading session, and its average trading remained 1.13 million shares. RNA dropped -7.47 % and it closed the trading at $4.71. The market capitalization of the stock remained 169.10 million. YTD trend of the stock was negative -75.53%. Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company’s primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease.
Has RNA Found The Bottom and Ready To Move Up? Find Out Here
AboutBest Stock on Demand
Beststocksondemand.com is an exciting online financial terminal where stock readers, traders and investors as well as market analysts can come to discover new opportunities, ideas, situations and news. Beststocksondemand.com goal is finding the most Undervalued or should we say Value Stocks or the Next Emerging Growth Stock that might be unnoticed by Wallstreet. Beststocksondemand.com is constantly searching for exceptional investment situations that can profit both investors and traders in order to grow their gains on a well balanced portfolio.
Beststocksondemand.com is also a well-respected marketing and research firm that mainly focuses on Best Stocks on Demand, Micro-Cap Stocks and Small Cap Stocks. Beststocksondemand.com uses its strategic corporate communication services to increase investor awareness of your company. We can support developing, emerging growth and deep-rooted companies in their marketing therefore creating a more dominant and operative investor alertness.
The assembled information disseminated by Beststocksondemand.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Beststocksondemand.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.
Please read Our Full Disclaimer at: http://www.beststocksondemand.com/disclaimer.html
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)